Advanced in Sandhoff Disease

Dr. Martin G. Pomper

Radiology | Nuclear Medicine
4940 Eastern Ave, 
Baltimore, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Sandhoff Disease
4940 Eastern Ave, 
Baltimore, MD 
OverviewInsuranceLocationsClinical Research

Overview

Martin Pomper is a Radiologist and a Nuclear Medicine provider in Baltimore, Maryland. Dr. Pomper is rated as an Advanced provider by MediFind in the treatment of Sandhoff Disease. His top areas of expertise are Neuroendocrine Tumor, Sandhoff Disease, Renal Cell Carcinoma (RCC), Prostatectomy, and Lithotripsy.

His clinical research consists of co-authoring 477 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Sandhoff Disease.

Specialties
Radiology
Nuclear Medicine
Licenses
Nuclear Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4940 Eastern Ave, Baltimore, MD 21224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Recruiting
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Study Phase: Phase 1/Phase 2
A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer
A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer
Enrollment Status: Terminated
Publish Date: May 06, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: DCFPyL
Study Phase: Early Phase 1
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Drug: Radium-223
Study Phase: Phase 2
A Study of PET Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1-directed Therapy
A Study of PET Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1-directed Therapy
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Drug
Study Drug: [18F]F-AraG Injection
Study Phase: Phase 1
A Phase 1 Study of [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
A Phase 1 Study of [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drug: 18F FLOR
Study Phase: Phase 1
Phase II Randomized Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr (ORIOLE) Trial
Phase II Randomized Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr (ORIOLE) Trial
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Radiation
Study Drug: DCFPyL-PET/MRI or -PT/CT
Study Phase: Phase 2
PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA
PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA
Enrollment Status: Terminated
Publish Date: February 18, 2022
Intervention Type: Radiation
Study Phase: Phase 1
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 29, 2020
Intervention Type: Drug, Procedure
Study Phase: Not Applicable
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

477 Total Publications

Today's Research, Tomorrow's Practice - White Paper from the Translation of New Therapy (TNT) Radiotheranostics Kick-off Pre-meeting of the Annual World Molecular Imaging Conference 2024.
Today's Research, Tomorrow's Practice - White Paper from the Translation of New Therapy (TNT) Radiotheranostics Kick-off Pre-meeting of the Annual World Molecular Imaging Conference 2024.
Journal: Molecular imaging and biology
Published: August 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pomper's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile